The Clinical Trials Core is a multidisciplinary effort designed to support the translational research of this SPORE. This resource will provide assistance in the design, conduct, and analysis of the clinical trials conducted within the spore. Specifically, assistance with translating laboratory findings into questions answerable within a clinical trial, clinical trial development, regulatory assistance with IND and IRB approvals, and clinical trial conduct will be provided. The core will provide research nursing, data management, adverse event reporting, and trial monitoring for the clinical trials. The core will assure the safety and confidentiality of the data within a pre-existing relational database with web interface. This core will support the laboratory core by managing the human investigation issues including obtaining informed consent from patients for the human tissue repository. The Core is directed by an experienced lymphoma clinical investigator with prior experience in database design. The Core Co-investigator is an experienced laboratory and clinical investigator experienced at moving laboratory findings into the clinic. Staff include Society of Clinical Research Associates certified data managers and experienced research nurses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA096888-01
Application #
6686621
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-20
Project End
2007-06-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jacene, Heather; Crandall, John; Kasamon, Yvette L et al. (2017) Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol 19:429-436
Welch, Jennifer J G; Schwartz, Cindy L; Higman, Meghan et al. (2017) Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv 1:681-684
Kanakry, Jennifer A; Gocke, Christopher D; Bolaños-Meade, Javier et al. (2015) Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant 21:2115-2122
Glaser, S L; Clarke, C A; Chang, E T et al. (2014) Hodgkin lymphoma incidence in California Hispanics: influence of nativity and tumor Epstein-Barr virus. Cancer Causes Control 25:709-25
Vendrame, Elena; Hussain, Shehnaz K; Breen, Elizabeth Crabb et al. (2014) Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 23:343-9
He, Jian; Wu, Jian; Jiao, Yuchen et al. (2013) Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma. J Neurooncol 114:275-9
Kanakry, Jennifer A; Li, Hailun; Gellert, Lan L et al. (2013) Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121:3547-53
Kanakry, Jennifer A; Kasamon, Yvette L; Bolaños-Meade, Javier et al. (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19:1514-7
Shamay, Meir; Hand, Nicholas; Lemas, M Victor et al. (2012) CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA. J Infect Dis 205:1095-9
Clark, Mary C; Pang, Mabel; Hsu, Daniel K et al. (2012) Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120:4635-44

Showing the most recent 10 out of 67 publications